Samsung Biologics has completed the purchase of Biogen’s stake in the Samsung Bioepis joint venture for $2.3 billion.   With the completion of the first payment of $1.0 billion pursuant to the terms of the acquisition agreement, Samsung Biologics has now fully acquired Samsung Bioepis as a wholly owned subsidiary. The remaining $1.3 billion will be made in installments over two years.   “Today’s announcement marks a significant milestone for Samsung Biologics in our continu...